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Abstract Chronic obstructive pulmonary disease is a smoking-related condition of progressive airflow obstruction, with 
disabling symptoms of chronic dyspnoea, cough and sputum production. In Spain, as in other countries worldwide, only a 
limited number of studies have attempted to quantify the impact of COPD on the patient, healthcare system and society. 
To obtain comprehensive information about the burden ofthis disease, an economic analysis of a large international survey, 
Confronting COPD in North AmeW and Europe, was conducted.The results of the economic analysis of data from the 
Spanish survey sample estimated that the annual cost of COPD to the healthcare system was e3238 per patient, with 
indirect costs amounting to E300 per patient, bringing the total societal cost of the disease to e3538 per patient per year: 
A significant proportion of the economic burden of COPD on the Spanish healthcare system was associated with inpatient 
hospitalization (E2708), which accounted for almost 84% of the total direct cost of the disease. As the major cause of 
inpatient hospitalization for COPD is acute exacerbations, these results highlight the need for interventions in the 
outpatient setting to prevent exacerbations in SpainThe impact of COPD on the healthcare system may also be due to 
the underdiagnosis and treatment of COPD, suggesting that costs may be reduced by improving the diagnosis and 
treatment of the disease in primary care.The sub-analysis of costs from the survey showed that patients with severe 
COPD were associated with considerably higher total societal costs than patients with mild disease (E9850 versus E I 3 I 6 
per patient).Therefore, introducing interventions to reduce the progression to severe COPD could also reduce the impact 
of the disease. 
0 2003 Elsevler Science Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease is a smoking- 
related condition of progressive airflow obstruction, with 
disabling symptoms of chronic dyspnoea, cough and 
sputum production. In developed countries worldwide, 
COPD is associated with considerable morbidity and 
mortality, and is predicted to become the third leading 
cause of death and the fifth leading cause of disability by 
the year 2020 ( I). 
In Spain, COPD is a relatively common disease, as 
shown by the results of a large, population-based 
epidemiological survey ( IBERPOC) in eight geographical 
regions (2). Patients with COPD were identified on the 
basis of smoking history, respiratory symptoms and 
spirometry measurements of lung function (meeting 
European Respiratory Society criteria for lung obstruction 
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i.e. FEV,/FVC ratio (forced expiratory volume in 
I second/forced vital capacity ratio) of 88% predicted in 
men and 89% predicted in women). COPD affected 9% of 
the population between the ages of 40 and 69 years.The 
prevalence of the disease was found to be three times 
higher in men (14.3%) than in women (3.9%), with 
considerable variation in the prevalence rate between 
different areas of the country (5-l 8%). By applying 
national population statistics to the prevalence rates 
calculated in the IBERPOC survey, it has been estimated 
that I .2 million people aged 40-70years in Spain have 
COPD. Using smoking rates to estimate the frequency of 
COPD in the general population, a disease model put the 
number of COPD sufferers at I .5 million in this country (3). 
Morbidity and mortality from COPD places a 
substantial burden on the Spanish healthcare system, and 
society as a whole. Based on national statistical and 
epidemiological data, an economic analysis of COPD in 
this country estimated the total societal cost of the 
disease at 140 billion pesetas (~Z84 I.42 million) 
(equivalent to 2% of the annual health department 
budget and 0.25% of gross internal product) (4). Around 
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65% of these costs were indirect, resulting from lost 
productivity due to long-term disability, temporary 
incapacity and premature death due to COPD, Direct 
costs (contacts with healthcare professionals, hospitaliza- 
tions and treatment costs) totalled 48 billion pesetas 
(8288.49 million). A prospective study of patients 
diagnosed with COPD or chronic bronchitis estimated a 
direct annual cost of 278000 pesetas (+Z 1670.8 I) per 
patient (5): more than double the per patient cost of 
asthma (I I3 280 pesetas, e680.83) (6). 
The burden of COPD on the Spanish healthcare 
system is particularly high in secondary care. The total 
cost of inpatient hospitalization in Spain was calculated at 
over I6 billion pesetas (e96. I6 million) in 1994: around 
one-third of the total direct costs of the disease (4). 
Hospital costs for COPD were higher than the costs of 
prescribed treatment (I 5 billion pesetas, e90* I5 million) 
or outpatient physician visits (6 billion pesetas, e36.06 
million) in this country Acute exacerbations of COPD 
are a major cause of emergency room visits and 
hospitalizations (7-9) with an average length of hospital 
stay of 9.9 days (7). The impact of exacerbations on 
hospital costs was highlighted by a recent study of over 
2400 Spanish patients with diagnosed COPD (I 0). The 
mean cost of managing an exacerbation of the disease in 
all patients was US$ I59 (8 160.60) (e I = US$O.99) per 
patient, of which US$92.29 (c93.22) was due to 
hospitalization. However, hospitalization accounted for 
92% of management costs in patients with treatment 
failure (defined as an unscheduled visit to a primary care 
practitioner, an increase in symptoms requiring a change 
in drug prescription, or an emergency room or hospital 
visit within I month of treatment for an exacerbation). 
The per patient cost of managing an exacerbation in 
patients with treatment failure totalled UQ.477.50 
(e482.32) (I 0). 
The burden of COPD on the secondary care in Spain 
may be a consequence of the underdiagnosis of the 
disease in primary care. Over three-quarters (78%) of 
the patients identified with COPD by the IBERPOC 
survey remained undiagnosed (2) and it has been 
estimated that over 80% of the total cost of COPD 
management in Spain may arise from the failure to 
diagnose the disease during the early stages (I I). The 
underdiagnosis of COPD may be partly due to the 
underutilization of spirometry by primary care 
practitioners: a recent survey of primary care practice 
revealed that many patients had not had their lung 
function assessed, despite having severe symptoms ( 12). 
In addition to the underutilization of spirometry, the 
underdiagnosis of COPD may be due to the reluctance 
of patients who smoke to consult their doctor for 
respiratory symptoms. Diagnosis of the disease relies on 
patients presenting with symptoms, as in Spain, there are 
no screening programmes in place to discover previously 
undiagnosed patients with the disease. 
Due to the low rates of COPD diagnosis in Spain, as 
many as 50% of patients with the disease may not receive 
treatment for the disease (2). When treatment for 
COPD is prescribed, treatment patterns differ in many 
aspects from those recommended by management 
guidelines in Spain (despite the guidelines being based on 
consensus between numerous physician societies) (I 2). 
Indeed, more money is spent on inappropriate treatment 
than on implementing recommended treatment 
strategies, primarily as a result of late diagnosis (I I). In 
addition to inadequacies in the everyday management of 
COPD symptoms, evidence suggests that the treatment 
of exacerbations in primary care may be sub-optima1.A 
prospective study of patients with COPD (n=24 14) 
found that exacerbations resulted in hospitalization in 
3.4% of cases (I 0). In a follow-up study of 2354 patients, 
a fifth of patients who received antibiotic treatment for 
respiratory infections returned to the practice for 
further treatment within 30 days because their 
symptoms were unresolved, and 3.3% of patients 
required subsequent hospital admission ( 13). 
Exacerbations may also be ineffectively treated in 
secondary care: a recent retrospective study of 1029 
patients with COPD found that the rate of readmission 
to hospital following an inpatient stay for an 
exacerbation of the disease was 4.8% (I 4). Therefore, 
poor exacerbation control is likely to be a major 
contributor to the burden of COPD on the secondary 
healthcare system. 
In Spain, as in other countries worldwide, only a 
limited number of studies have attempted to quantify the 
impact of COPD on the patient, healthcare system and 
society.To obtain comprehensive information about the 
impact of the disease, a large international survey, 
Confronting COP0 in North America and Europe, was 
conducted in patients and physicians from eight 
countries. The survey included patients with diagnosed 
and undiagnosed COPD, and collected information on 
clinical outcomes, healthcare resource utilization and 
direct costs, COPD-related productivity loss, and 
indirect costs resulting from patient work absence.The 
clinical results of the survey showed that COPD was 
underdiagnosed and undertreated, resulting in 
considerable ill-health and disability (I 5). This paper 
reports the results of the economic analysis of 
healthcare resource use and lost productivity reported 
by the Spanish sample. 
METHODS 
Survey details 
The methodology used in the economic analysis of the 
Confronting COPD survey is described in detail 
elsewhere (I 6). Briefly, a telephone interview survey was 
carried out in a sample of 3265 patients and 905 
physicians from Canada, France, Germany, Italy, the 
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Netherlands, Spain, the U.K. and the U.S.A. In each 
country, patients were asked questions about their 
COPD-related hospitalizations, emergency room visits, 
primary care consultations, treatment, and laboratory 
tests, for the I2-month period prior to the survey. In all 
countries except Germany, patient responses were used 
to derive quantitative measures of healthcare resource 
utilization, which were then used to calculate the mean 
direct cost of COPD per patient. Information on time 
lost from work due to COPD was also collected, and 
used to estimate the indirect cost of patient work loss. 
Direct and indirect costs were summed to give an 
estimate of the mean per patient cost of COPD to 
society. Finally, annual direct, indirect and total costs were 
analysed in terms of disease severity and other patient 
characteristics, such as sex and smoking status. 
Cost calculations 
Unit costs applicable to healthcare resource use and lost 
productivity in Spain were derived by local experts, for 
use in the economic analysis of the survey data (Table I). 
The unit cost of inpatient hospitalization included the 
cost of a chest X-ray, a computerized tomography (CT) 
scan (also known as computerized axial tomography: 
CAT), a magnetic resonance imaging (MRI) scan, or an 
electrocardiogram (ECG). Unit costs for a day lost from 
work were calculated on the basis that both men and 
women in Spain would be expected to retire at the age 
of 65 years. 
RESULTS 
Patient characteristics 
The demographics and clinical characteristics of patients 
included in the Spanish arm of the survey are shown in 
Table 2. Patients ranged from 45 to 96 years of age, and 
77.4% were male.Almost all the patients had a previous 
smoking history, and just under two-fifths of patients 
reported that they were current smokers. The mean 
number of pack years smoked was 55, with a maximum 
of 480 pack years reported. More than half (54%) of the 
patients had been previously diagnosed with chronic 
bronchitis, although one in six patients (16%) remained 
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undiagnosed despite experiencing persistent coughing 
with sputum production for at least 2 years. Three- 
quarters (77%) of the patients surveyed thought that 
their COPD was mild or moderate, with severe COPD 
reported by 18% of patients. One-third of patients 
reported comorbidities, including kidney problems 
(I 8%), diabetes, heart disease, arthritis and rheumatism 
(each affecting 4% of the patient sample). 
Hospital visits and healthcare 
professional contacts 
In Spain, the majority (61%) of patients with COPD 
usually went to their primary care practitioner (PCP) for 
the treatment of their condition. Nearly two-fifths of 
patients (39%) were currently receiving treatment from 
a specialist in internal medicine, respiratory disease, 
cardiology, allergy or some other discipline. The 
proportion of patients reporting scheduled and 
unscheduled visits with healthcare professionals is shown 
in Fig. I .Although the majority of healthcare professional 
contacts were scheduled (Table 3) 7% of patients had 
unscheduled PCP visits and 4% of patients had 
unscheduled specialist visits during the year prior to the 
survey. During the year prior to the survey, a maximum 
of 20 unscheduled PCP visits and 35 unscheduled 
specialist visits were reported by respondents. 
One-third of patients (35%) had been hospitalized for 
COPD at some time in their lives, with one-fifth of 
patients reporting an inpatient stay during the I2-month 
period prior to the survey (Fig. I). Over 400 
hospitalizations were recorded (equivalent to a mean of 
4.9 per patient reporting). In addition, one-fifth of 
patients with COPD had visited the emergency room for 
treatment in the past year, with a maximum of 40 visits 
reported during this period (Table 3). 
COPD treatment 
Less than three-fifths (58.2%) of patients in the Spanish 
sample of the survey were taking prescribed medication 
for the treatment of COPD. In these patients, short- 
acting &-agonists were the most commonly prescribed 
treatment option, followed by anticholinergics, inhaled 
corticosteroids and theophylline (Fig. 2). Around one- 
quarter of patients (27. I %) administered medication 
using a nebulizer. 
In the year prior to the survey, more than two-fifths of 
patients (45%, n= I8 I) had received a course of 
antibiotics for the treatment of respiratory infections 
(Table 4).Around 42% of patients in the survey had not 
received an influenza vaccination (aimed at preventing 
the occurrence of COPD exacerbations). A requirement 
for home oxygen therapy was reported by 12% of 
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FIGURE I. Percentage of patients reporting healthcare resource use/contacts during the I2 months prior to the survey 
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FIGURE 2. Use of prescribed medications by patients in the Spanish sample. 
patients (n=48), with an estimated total of I5 5 IO days 
use (over 300 days use per patient using oxygen). 
Laboratory investigations 
It was estimated that the patients in the Spanish sample 
of the Confronting COPD survey had a total of 1704 
laboratory tests during the previous year, equivalent to a 
mean of 4.2 tests per patient. Around half of patients 
received a chest X-ray or ECG, with one-third of 
patients reporting tests of blood oxygen (Table 5). Only 
15% of patients with COPD had received a CT (CAT) or 
MRI scan. 
Work loss due to COPD 
Over one-third (36%) of patients in the Spanish sample 
were under retirement age.The lost productivity analysis 
of the data from the survey revealed that 9% of patients 
with COPD were prevented from working because of 
their condition, and 8% of patients were limited in their 
ability to work.Work absenteeism was reported by 3% 
of patients, with an estimated total of 2263 days lost. In 
addition, 4% of patients (n= 15) reported that their 
caregiver missed work as a result of their illness, with a 
total of 86 days of work lost. 
Direct costs 
Using the healthcare resource utilization data collected 
from the Spanish sample, the annual cost of COPD to 
the healthcare system was estimated at e3238. I8 per 
patient (Table 6). Over 86% of these costs were 
accounted for by unscheduled emergency care for 
COPD (inpatient hospitalizations 83.6%; emergency 
room, unscheduled PCP or specialist visits 2.9%) (Fig. 3). 
Although almost 2500 scheduled visits to healthcare 
professionals were reported by patients in the survey, 
these visits accounted for only 5. I %  of the annual direct 
per patient costs of COPD.Treatment for COPD cost an 
estimated ~Z249.94 per patient, and almost three-fifths of 
(57.5%) treatment costs were for home oxygen therapy. 
Regular prescription medication accounted for less than 
40% of treatment costs, and less than 3% of the total 
direct cost of COPD (Fig. 3,Table 6).The annual cost of 
primary care/outpatient laboratory tests for COPD was 
estimated at E 18.09 per patient. 
Total societal cost 
In addition to the direct cost of the disease, patient work 
loss due to COPD was associated with a mean annual 
cost of 8300.25 per patient.The annual per patient cost 
of COPD to society totalled e3538.53 per patient. 
Sub-analysis of costs and patient 
characteristics 
A sub-analysis of the annual direct, indirect and total 
societal costs of COPD from the Spanish survey was 
conducted to assess the relationship between disease 
severity and per patient costs. Patients were classified as 
having mild, moderate or severe COPD, based on their 
self-perceived severity ratings. The results showed that 
patients with severe COPD had substantially higher 
annual societal costs per patient than those with 
moderate or mild COPD (Fig. 4). 
Relationships between costs and other patient 
characteristics (sex, smoking status, comorbidity and 
education level) were also assessed using the Spanish 
survey data (Table 7). Direct, indirect and total societal 
costs were higher in males than females, and patients with 
comorbidities compared with patients without chronic 
illness other than COPD. Direct and total societal costs 
were higher in former smokers than current smokers, 
and in patients who were not educated beyond basic 
schooling compared with educated patients. However, 
current smokers and educated patients were particularly 
costly in terms of indirect costs. 
DISCUSSION 
The Confronting COPD survey assessed the use of 
healthcare resources and lost productivity in patients 
with diagnosed COPD and patients with chronic 
bronchitis (identified by persistent dyspnoea, coughing 
and sputum production for at least 2 years) who 
remained undiagnosed. An economic analysis was 
conducted from the societal perspective, including the 
direct and indirect costs of the disease. 
In Spain, the majority of patients usually visited their 
primary care practitioner for the overall management of 
their condition, though two-fifths of patients were under 
the care of a specialist based in primary care or within a 
hospital outpatient department. One-fifth of patients 
reported an inpatient hospitalization or an emergency 
room visit due to COPD in the past year.The direct cost 
of healthcare contacts, hospital visits, medication use and 
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FIGURE 3. Percentage breakdown of annual direct costs of COPD for the Spanish sample. 
laboratory tests for COPD was estimated at E3238 per treatment guidelines for 
patient, accounting for over 9 I % of the total societal cost 
of COPD in the survey.The mean indirect cost arising 
from patient work loss was E300 per patient. 
A significant proportion of the economic burden of 
COPD on the Spanish healthcare system was associated 
with inpatient hospitalization, which accounted for 
almost 84% of the total direct cost of the disease.As the 
major cause of inpatient hospitalization for COPD is 
acute exacerbations, these results highlight the need for 
interventions to prevent exacerbations in the outpatient 
setting.The main strategy recommended by international 
reducing the risk of 
exacerbations in patients with COPD is influenza 
vaccination (17) though 40% of patients had not been 
vaccinated during the I2 months prior to the survey. 
Indeed, many patients in the survey sample appeared to 
experience an exacerbation caused by respiratory 
infection, as shown by the two-fifths of patients who 
reported using antibiotics in the past year.This suggests 
a need for treatment options that can reduce the risk of 
exacerbations in patients with COPD. At present, 
treatment options for COPD focus on bronchodilators, 
which although able to increase lung function and 
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FIGURE 4. Annual societal cost of COPD by disease severity. 
improve symptom control, are limited in their ability to 
prevent acute episodes of severe symptoms. Reducing 
the frequency and severity of exacerbations is likely to 
require medications that act upon the underlying 
inflammatory processes of the disease. 
In addition to acute exacerbations, the inadequate 
management of daily symptoms of COPD can add to the 
direct cost of the disease. Confirming the results of 
previous studies, the survey suggested that COPD was 
underdiagnosed in Spain, as one in six patients who had 
chronic bronchitis as defined by symptom criteria had 
not received a diagnosis. Underdiagnosis contributes to 
the burden of COPD by limiting the number of patients 
who receive appropriate medication, which in turn 
increases the likelihood of available expenditure being 
used to prescribe non-recommended medications that 
may be ineffective.The survey showed that many patients 
with COPD were not receiving any regular prescribed 
medication for the disease, and almost one-fifth of 
patients stated that their symptoms were poorly or not 
at all controlled. Poor symptom management may 
increase direct costs by increasing patient need for 
unscheduled care visits (emergency room visits, and 
contacts with primary care practitioners). 
As a likely consequence of the underdiagnosis and 
subsequent undertreatment of patients in the Spanish 
survey sample, the costs of prescribed medication were 
relatively low, accounting for less than 3% of the direct 
costs of the disease per patient.This result is in contrast 
to previous analyses of COPD healthcare costs in Spain, 
which have shown that drug treatment is a major driver 
of the direct costs of this disease (4,7,l I, 14). The 
differences between the costs of medication in the 
current survey and other studies might be expected, 
given that cost calculations were previously restricted to 
patients with a confirmed diagnosis of COPD, who are 
more likely to receive regular prescribed medication 
than patients who remain undiagnosed. In any case, some 
variability in costs between separate studies of COPD 
patients in the same country will inevitably arise from 
differences in the methods used to assess healthcare 
resource utilization (e.g. self-report versus patient 
databases), and in the unit costs used to calculate the 
economic impact of the disease. 
A sub-analysis of direct costs from the survey showed 
that direct costs in patients with severe COPD were 
over seven times higher than in patients with mild 
COPD.This suggests that interventions designed to delay 
the progression of disease, such as smoking cessation, 
could alleviate the future impact of COPD on the 
healthcare system. However, research has shown that it 
may be possible to reduce the impact of severe COPD 
THE BURDEN OF COPD IN SPAIN S69 
today, by shifting the focus of care away from hospital 
treatment. A recent study conducted in Spain showed 
that the introduction of a hospital-based home care 
service for patients with severe COPD decreased the 
need for hospital admissions and the length of hospital 
stay, resulting in considerable cost-savings to the 
healthcare system (9). 
CONCLUSIONS 
In Spain, the Confronting COPD survey showed that 
COPD is costly to the healthcare system and society.The 
burden of COPD is particularly high in secondary care as 
a result of acute disease exacerbations, which highlights 
the need for interventions to prevent exacerbations in 
the outpatient setting. Improving the diagnosis and 
treatment of the disease in primary care, and introducing 
interventions to reduce the impact of severe COPD on 
the healthcare system, could also reduce the impact of 
the disease in this country. 
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